ENTO

Entero Therapeutics
ENTO

Overview Fund Activity

5 hedge funds and large institutions have $18.4K invested in Entero Therapeutics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 11 closing their positions.

Holders
5
Holders Change
-11
Holders Change %
-68.75%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
5
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

1
TRCT
1
Tower Research Capital (TRC)
New York
$11.9K
2
Citadel Advisors
2
Citadel Advisors
Florida
$0
3
VF
3
Virtu Financial
New York
$0
4
Geode Capital Management
4
Geode Capital Management
Massachusetts
$0
5
OAC
5
OMERS Administration Corp
Ontario, Canada
$0
Name Market Value Shares Shares
Change 		Shares
Change %
TRCT
1
Tower Research Capital (TRC)
New York
$11.9K 2,836 -8,333 -75%
UBS Group
2
UBS Group
Switzerland
$6.46K 1,537 -145 -9%
Wells Fargo
3
Wells Fargo
California
$25 6 -75 -93%
US Bancorp
4
US Bancorp
Minnesota
$4 1 -23 -96%
KSWA
5
Kathleen S. Wright Associates
Pennsylvania
$4 1 -21 -95%
Citadel Advisors
6
Citadel Advisors
Florida
– – -81,859 Closed
VF
7
Virtu Financial
New York
– – -50,973 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– – -42,340 Closed
OAC
9
OMERS Administration Corp
Ontario, Canada
– – -29,800 Closed
HF
10
HRT Financial
New York
– – -17,825 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– – -16,478 Closed
State Street
12
State Street
Massachusetts
– – -11,797 Closed
Osaic Holdings
13
Osaic Holdings
Arizona
– – -1,000 Closed
BlackRock
14
BlackRock
New York
– – -376 Closed
CPG
15
Cornerstone Planning Group
New Jersey
– – -14 Closed
First Manhattan
16
First Manhattan
New York
– – -1 Closed
CFGS
17
Concourse Financial Group Securities
Alabama
– – – –